Biostem Technologies

Biostem Technologies Intangible Assets

The Intangible Assets of Biostem Technologies (BSEM) as of Oct 9, 2026 is 224,100.00 USD. In the previous year, Intangible Assets was 347,600.00 USD — a change of -35.53% (lower).

Intangible Assets

224,100.00USD

YoY

-35.53%

Last updated:

Intangible Assets of Biostem Technologies is 2024 224,100.00 USD. Intangible Assets of Biostem Technologies was 2023 347,600.00 USD. It decreases by -35.53% lower compared to the previous year.

The Biostem Technologies Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2015
167,700.00 USD
Jan 1, 2016
470,000.00 USD
Jan 1, 2017
280,000.00 USD
Jan 1, 2021
210,000.00 USD
Jan 1, 2023
347,600.00 USD
Jan 1, 2024
224,100.00 USD
The Biostem Technologies Intangible Assets history
YEARIntangible AssetsYoY
224,100.00USD-35.53%
347,600.00USD+65.52%
210,000.00USD-25.00%
280,000.00USD-40.43%
470,000.00USD+180.26%
167,700.00USD—
Access this data via the Eulerpool API

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Intangible Assets of Biostem Technologies is 224,100.00 USD in 2024.

Intangible Assets of Biostem Technologies changed from 347,600.00 USD to 224,100.00 USD, representing a -35.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Biostem Technologies historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Biostem Technologies

All Key Metrics — Biostem Technologies